Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05242744 · ClinicalTrials.gov registry record
FTT PET/CT in Metastatic Prostate Cancer
A clinical trial of Prostate Cancer Metastatic, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05242744 is a study of Prostate Cancer Metastatic that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants, below the 226-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05242744, a study of Prostate Cancer Metastatic, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05242744
The ClinicalTrials.gov registry entry for NCT05242744 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (87% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which [18F]FluorThanatrace is the first listed.
NCT05242744 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05242744 about?
NCT05242744 is a clinical study titled "FTT PET/CT in Metastatic Prostate Cancer". Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a cl...
What is the current status of trial NCT05242744?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2026-07.
What conditions does trial NCT05242744 study?
This clinical trial studies the following conditions: Prostate Cancer Metastatic.
What interventions are being tested in trial NCT05242744?
The interventions under investigation include: [18F]FluorThanatrace (DRUG).
Who is sponsoring clinical trial NCT05242744?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05242744 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
RECRUITING · NA
-
Castrate Resistant Prostate Cancer Enhertu Therapy
RECRUITING · Phase 2
-
Exercise in Prostate Cancer
RECRUITING · NA
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
-
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
RECRUITING · Phase 3
-
Geriatric Assessment and Technology Evaluation in Prostate Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.